An overview on nanocarriers

Recent Trends in Curcumin-Containing Inorganic-Based Nanoparticles Intended for In Vivo Cancer Therapy

“…Mesoporous silica nanoparticles (MSNPs) are inorganic nanoparticles or mesoporous forms of silica with particle sizes between 30 and 300 nm that can promote endocytosis by target cells with minimal toxicity [ 73 ]. MSNPs are of special interest because of their excellent biocompatibility, high drug-loading capacity, rigid framework, well-defined pore structure, easily controllable morphology, and tunable surface chemistry [ 74 , 75 ].…”

A Comprehensive Review of Essential Oil–Nanotechnology Synergy for Advanced Dermocosmetic Delivery

“…One notable application of this synergy involves integrating nanomaterials into formulations infused with essential oils, capitalizing on their combined potential to target specific skin layers effectively [153,154]. Nanocarriers, ranging from liposomes to solid lipid nanoparticles, act as efficient vessels for encapsulating bioactive compounds present in essential oils, ensuring their potency while facilitating precise delivery to the skin [155,156]. When encapsulated within these nanocarriers alongside essential oils, peptides renowned for stimulating collagen synthesis penetrate deeper skin layers, initiating a rejuvenating cascade that enhances skin elasticity and resilience [57,67].…”

Development and optimization of vildagliptin solid lipid nanoparticles loaded ocuserts for controlled ocular delivery: A promising approach towards treating diabetic retinopathy

“…SLNPs are an effective ocular drug delivery technology due to their mucoadhesive characteristics, sterilization tolerance, increased corneal absorption, prolonged ocular retention time, and sustained drug release profile without compromising visual acuity ( Akhter et al, 2022 ). The development of SLNPs as carriers for water-soluble compounds has proven challenging, despite their use as a delivery system for lipophilic medicines ( Paul et al, 2022 ). The ability to accurately deliver an ophthalmic drug delivery system without causing blurred vision or eye irritation, having an appropriate mucoadhesive time to improve drug retention in the pre-corneal area and thereby increase drug bioavailability, having limited systemic absorption through nasolacrimal drainage, and reducing the need for frequent dosing regimens leading to improved outcomes are generally the main requirements for an ideal ophthalmic drug delivery system.…”